Scott A. Kono
Emory University
24 Papers
150 Citations
Scott A. Kono is an academic researcher from Emory University. The author has contributed to research in topics: Epidermal growth factor receptor & Cancer. The author has an hindex of 16, co-authored 22 publications. Previous affiliations of Scott A. Kono include University of Colorado Denver & Anschutz Medical Campus.
Chat about Author
Papers
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.
Christopher L. Ellington,Michael Goodman,Scott A. Kono,William Grist,Trad Wadsworth,Amy Y. Chen,Taofeek K. Owonikoko,Suresh S. Ramalingam,Dong M. Shin,Fadlo R. Khuri,Jonathan J. Beitler,Nabil F. Saba +11 more
TL;DR: The authors aimed to analyze incidence rates and survival outcomes for patients diagnosed with ACCHN using national population‐based data.
330
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge,Scott A. Kono,Xian Lu,Sonia Okuyama,Anna E. Barón,Ana B. Oton,Angela M. Davies,Marileila Varella-Garcia,Wilbur A. Franklin,Robert C. Doebele +9 more
TL;DR: In this exploratory analysis, ALK-positive patients have a significantly longer PFS on pemetrexed compared with triple-negative patients, whereas EGFR or KRAS mutant patients do not.
247
Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
Marianne E. Marshall,Trista K. Hinz,Scott A. Kono,Katherine R. Singleton,Brady Bichon,Kathryn E. Ware,Lindsay Marek,Barbara Frederick,David Raben,Lynn E. Heasley +9 more
TL;DR: The HNSCC cell lines can be divided into subsets defined by sensitivity to EGFR and FGFR-specific TKIs, andFGFR inhibitors may represent novel therapeutics to deploy alone or in combination with EGFR inhibitors in H NSCC.
127
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.
TL;DR: Due to the high degree of homology of FGFRs with VEGFRs and PDGFRs, FGFR-active TKIs already exist and could be rapidly advanced into clinical investigations as FGFR inhibitors as a means to expand the spectrum of NSCLC patients that can be effectively targeted with TKI-directed therapies.
75
HPV Positive Squamous Cell Carcinoma of the Oropharynx. Are we Observing an Unusual Pattern of Metastases
TL;DR: Four patients with HPV+ oropharyngeal squamous cell carcinoma (OPSCC) were identified retrospectively based on unanticipated clinical behavior and two patients died of their disease, one patient is alive with disease and one patients is disease-free.
66